Platelet function profile post-clopidogrel therapy in patients with type 2 diabetes undergoing coronary stent implantation

Clinical and Applied Thrombosis/Hemostasis

Volumn 18, Issue 3, 2012, Pages 249-257

  Saad, Abeer Attia ^a   Ismail, Eman Abdel Rahman ^a   Darwish, Yasser Wagih ^a   Nasr, Hesham Ahmed ^b   Hassan, Abdel Rahman ^b   Bedeer, Ibrahim ^b   Alfons, Marian Adel ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b NATIONAL HEART INSTITUTE   (Egypt)

Author keywords

clopidogrel; coronary stent implantation; diabetes; platelet

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; HEMOGLOBIN A1C; PADGEM PROTEIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; CORONARY STENT; FEMALE; FLOW CYTOMETRY; GLYCEMIC CONTROL; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; IMPLANTATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION;

AGED; CORONARY VESSELS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; STENTS; TICLOPIDINE;

EID: 84860704258     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029611427899     Document Type: Article

References (63)

1. Gurbel PA, Bliden KP, Hayes KM, Tantry U.. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther. 1999 ; 2 (4). 535-545
2. Massberg S, Schulz C, Gawaz M.. Role of platelets in the pathophysiology of acute coronary syndrome. Semin Vasc Med. 2003 ; 3 (2). 147-162
3. Samara WM, Gurbel PA.. The role of platelet receptors and adhesion molecules in coronary artery disease. Coron Artery Dis. 2003 ; 14 (1). 65-79 (Pubitemid 36337819)
4. Luscher TF, Creager MA, Beckman JA, Cosentino F.. Diabetes and vascular disease: pathophysiology, clinical consequences and medical therapy. Circulation. 2003 ; 108 (13). 1655-1661 (Pubitemid 37187795)
5. Vericel E, Januel C, Carreras M, Moulin P, Lagarde M.. Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. Diabetes. 2004 ; 53 (4). 1046-1051 (Pubitemid 38436617)
6. Beckman JA, Creager M, Libby P.. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002 ; 287 (19). 2570-2581 (Pubitemid 34517204)
7. Colwell JA, Nesto RW.. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003 ; 26 (7). 2181-2188
8. Ferroni P, Basili S, Falco A, Davi G.. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004 ; 2 (8). 1282-1291 (Pubitemid 40186123)
9. Kunapuli SP, Dorsam RT, Soochong K, Quinton TM.. Platelet purinergic receptors. Curr Opin Pharmacol. 2003 ; 3 (2). 175-180 (Pubitemid 36411242)
10. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001 ; 409 (6817). 202-207 (Pubitemid 32144286)
11. Dorsam RT, Kunapuli SP.. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004 ; 113 (3). 340-345 (Pubitemid 38544175)
12. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000 ; 84 (5). 891-896
13. Steinhubl SR, Berger PB, Mann JT, et al. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 ; 288 (19). 2411-2420 (Pubitemid 35340537)
14. Mehta SR, Yusuf S, Peters RJ, et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001 ; 358 (9281). 527-533 (Pubitemid 32772726)
15. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK.. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 ; 345 (7). 494-502 (Pubitemid 32758501)
16. Steinhubl SR, Talley JD, Braden GA, et al. Point of care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation. 2001 ; 103 (21). 2528-2530
17. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM.. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003 ; 107 (23). 2908-2913 (Pubitemid 36736631)
18. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res. 2005 ; 115 (1-2). 101-108 (Pubitemid 39572762)
19. Sanderson S, Emery J, Baglin T, Kinmonth AL.. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med. 2005 ; 142 (5). 370-380 (Pubitemid 40293410)
20. Feher G, Feher A, Pusch G, et al. Clinical importance of aspirin and clopidogrel resistance. World J Cardiol. 2010 ; 2 (7). 171-186
21. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events poststenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol. 2005 ; 46 (10). 1820-1826 (Pubitemid 41579802)
22. Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol. 2005 ; 46 (10). 1827-1832 (Pubitemid 41579803)
23. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007 ; 49 (24). 2312-2317 (Pubitemid 46891710)
24. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006 ; 27 (20). 2420-2425 (Pubitemid 44522148)
25. Foo F, Oldroyd KG.. Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention. Biomark Med. 2011 ; 5 (1). 9-30
26. Musallam KM, Charafeddine K, Bitar A, et al. Resistance to aspirin and clopidogrel therapy. Int J Lab Hematol. 2011 ; 33 (1). 1-18
27. Geiger J, Teichmann L, Grossmann R, et al. Monitoring of clopidogrel action: Comparison of methods. Clin Chem. 2005 ; 51 (6). 957-965 (Pubitemid 40740875)
28. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M.. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003 ; 89 (5). 783-787 (Pubitemid 36603418)
29. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005 ; 54 (8). 2430-2435 (Pubitemid 41134272)
30. Singla A, Antonino MJ, Bliden KP, Tantry US, Gurbel PA.. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J. 2009 ; 158 (5). 784.e1 - e6
31. Geisler T, Anders N, Paterok M, et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care. 2007 ; 30 (2). 372-374 (Pubitemid 46198349)
32. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2006 ; 29 (suppl 1). S43 - S48
33. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost. 2006 ; 4 (3). 542-549
34. Wenaweser P, Rey C, Eberli FR, et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J. 2005 ; 26 (12). 1180-1187 (Pubitemid 40863124)
35. Sbrana S, Della Pina F, Rizza A, et al. Relationships between optical aggregometry (Type Born) and flow cytometry in evaluating ADP-induced platelet activation. Cytometry B Clin Cytom. 2008 ; 74 (1). 30-39
36. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study. J Invasive Cardiol. 2004 ; 16 (6). 325-329 (Pubitemid 38715816)
37. Gurbel PA, Serebruany VL, Shustov AR, et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. J Am Coll Cardiol. 1998 ; 31 (7). 1466-1473 (Pubitemid 28273286)
38. Ruggeri ZM.. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol. 1994 ; 31 (3). 29-39
39. Gawaz M, Neumann FJ, Schömig A.. Evaluation of platelet membrane glycoproteins in coronary artery disease: consequences for diagnosis and therapy. Circulation. 1999 ; 99 (1). E1 - E11
40. Gurbel PA, Kereiakes DJ, Dalesandro MR, Bahr RD, O'Connor CM, Serebruany V.. Role of soluble and platelet-bound p-selectin in discriminating cardiac from non-cardiac chest pain at presentation in the emergency department. Am Heart J. 2000 ; 139 (2 Pt 1). 320-328 (Pubitemid 30090810)
41. Gorchakova O, von Beckerath N, Gawaz M, et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J. 2004 ; 25 (21). 1898-1902 (Pubitemid 39452606)
42. Wiviott SD, Antman EM.. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation. 2004 ; 109 (25). 3064-3067
43. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv. 2003 ; 59 (3). 295-302 (Pubitemid 36792384)
44. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004 ; 109 (25). 3171-3175
45. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US.. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol. 2005 ; 45 (9). 1392-1396 (Pubitemid 40615608)
46. Samara WM, Bliden KP, Tantry US, Gurbel PA.. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res. 2005 ; 115 (1-2). 89-94 (Pubitemid 39572760)
47. Gurbel PA, Antonino MJ, Bliden KP, et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets. 2008 ; 19 (8). 595-604
48. Grant PG.. Diabetes mellitus as a prothrombotic condition. J Int Med. 2007 ; 262 (2). 157-172
49. Angiolillo DJ, Shoemaker SB, Desai B, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation. 2007 ; 115 (6). 708-716 (Pubitemid 46294761)
50. Zurakowski A, Wojakowski W, Dzielski T, et al. Plasma levels of C-reactive protein and interleukin-10 predict late coronary in-stent restenosis 6 months after elective stenting. Kardiol Pol. 2009 ; 67 (6). 623-630
51. Nesto RW.. (2004) Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med. 2009 ; 116 (suppl 5A). 11S - 22S (Pubitemid 38333037)
52. Gaborit B, Frère C, Cuisset T, Alessi MC, Dutour A.. Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently related to plasma fibrinogen level but not to glycemic control. J Thromb Haemost. 2009 ; 7 (11). 1939-1941
53. Campo G, Fileti L, Valgimigli M, et al. Poor response to clopidogrel: current and future options for its management. J Thromb Thrombolysis. 2010 ; 30 (3). 319-331
54. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004 ; 109 (2). 166-171 (Pubitemid 38114134)
55. Watala C, Golanski J, Pluta J, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin): its relation to metabolic control. Thromb Res. 2004 ; 113 (2). 101-113 (Pubitemid 38534487)
56. Wang L, Wang X, Chen F.. Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents. Drugs R D. 2010 ; 10 (4). 219-224
57. Lee S-W, Park S-W, Hong M-K, et al. Triple versus dual antiplatelet therapy after coronary artery stenting: impact on stent thrombosis. J Am Coll Cardiol. 2005 ; 46 (10). 1833-1837 (Pubitemid 41579804)
58. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention. Circulation. 2005 ; 111 (25). 3366-3373
59. Keller PF, Carballo D, Roffi M.. Diabetes and acute coronary syndrome. Minerva Med. 2010 ; 101 (2). 81-104
60. Paniccia R, Antonucci E, Maggini N, et al. Light transmittance aggregometry induced by different concentrations of adenosine diphosphate to monitor clopidogrel therapy: a methodological study. Ther Drug Monit. 2011 ; 33 (1). 94-98
61. Peace AJ, Egan K, Kavanagh GF, et al. Reducing intra-individual variation in platelet aggregation: implications for platelet function testing. J Thromb Haemost. 2009 ; 7 (11). 1941-1943
62. Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL.. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction of New Thrombus Occurrence (PRONTO) trial. Am Heart J. 2003 ; 145 (2). 239-247 (Pubitemid 36207944)
63. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006 ; 48 (9). 1742-1750 (Pubitemid 44648629)